Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0252 • ACR Convergence 2020
Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
Julie Birt¹, Jianmin Wu¹, Kirstin Griffing¹, Natalia Bello², Nicole Princic³, Isabelle Winer³, Carolyn Lew³ and Karen Costenbader⁴, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, ³IBM Watson Health, Cambridge, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is managed by variable combinations of five drug classes: antimalarials, biologics, corticosteroids, non-steroidal anti-inflammatory agents, and immunosuppressants. Opioids are commonly prescribed to SLE…
Abstract Number: 0269 • ACR Convergence 2020
Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
Ehizogie Edigin¹, Precious Eseaton², Pius Ojemolon³ and Augustine Manadan⁴, ¹John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin Teaching Hospital, Benin, ³St. George's University, St. George's, Grenada, ⁴Cook County Hospital/Rush University Medical center, Chicago, IL
Background/Purpose: Libman-Sacks endocarditis characterized by thrombotic and/or non-infective sterile inflammatory vegetations are common in Systemic Lupus Erythematosus (SLE) and associated with increased morbidity. These vegetations…
Abstract Number: 0286 • ACR Convergence 2020
An SLE-linked ITGAM Gene Variant Changes Mac-1 Structure, Signaling, and Surface Expression and Enhances IFNg Production and Antigen Presentation by B Cells
Joseph Blake¹, Alexander Szalai², Jeffrey Edberg³ and James Mobley³, ¹UAB, Birmingham, ²University of Alabama at Birmingham, birmingham, AL, ³UAB, Birmingham, AL
Background/Purpose: SLE is a chronic and debilitating disease; in the USA with an estimated incidence of 3-10 per 100,000 people and currently affecting an estimated…
Abstract Number: 0303 • ACR Convergence 2020
SLE Patients Stratify into Distinct Clusters Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare
Kieran Manion¹, Carolina Munoz-Grajales², Michael Kim³, Kirubel Goliad⁴, Dennisse Bonilla⁵, Dafna Gladman¹, Murray Urowitz⁶, Zahi Touma⁷ and Joan Wither⁵, ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto-UHN, Toronto, ON, Canada, ³Krembil Research Insitute, Toronto, ON, Canada, ⁴University of Toronto-UHN, Toronto, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE is a chronic autoimmune disease in which periods of quiescence are interspersed with acute flares of disease activity that produce much of the…
Abstract Number: 0519 • ACR Convergence 2020
Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid
Rohan Willis¹, E Nigel Harris², Vijaya Murthy³, Zurina Romay-Penabad¹, Alvaro Schleh⁴, Monica Smikle², Karel De Ceulaer², Anne Tebo⁵, Troy Jaskowski⁶, Marta Guerra⁷, David Ware Branch⁸, Jane Salmon⁷, Michelle Petri⁹ and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³University of Texas Medical Branch, League City, TX, ⁴Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁵Department of Pathology, University of Utah, Salt Lake City, ⁶ARUP Laboratories, Salt Lake City, UT, ⁷Hospital for Special Surgery, New York, NY, ⁸University of Utah, Salt Lake City, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard…
Abstract Number: 0739 • ACR Convergence 2020
Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of Systemic Lupus Erythematosus
Chang-Hee Suh¹, Wook-Young Baek¹, Ji-Won Kim¹, Yang-Seon Choi², Sung-Min Lee¹, In-Ok Son¹, Ki-Woong Jeon¹ and Sangdun Choi², ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Ajou University, Suwon, Republic of Korea
Background/Purpose: Toll-like receptors (TLRs) are a type of protein that plays a major role in the innate immune system. In recent years, several studies have…
Abstract Number: 0853 • ACR Convergence 2020
Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) patients are usually treated with glucocorticoids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid…
Abstract Number: 0871 • ACR Convergence 2020
Hydroxychloroquine Dose Reduction and SLE Flares
April Jorge¹, Gary Ho², Michael Wu², Karen Costenbader³ and Hyon Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: 2016 ophthalmology guidelines recommend using hydroxychloroquine (HCQ) dosages < 5mg/kg/day, which is lower than the traditional 400mg/day for the majority of SLE patients. However,…
Abstract Number: 0987 • ACR Convergence 2020
Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
Joan Merrill¹, Victoria Werth², Richard Furie³, Ronald van Vollenhoven⁴, Milan Petronijevic⁵, Benito Velasco Zamora⁶, Maria Majdan⁷, Fedra Irazoque-Palazuelos⁸, Michael Weiswasser⁹, Shimon Korish⁹, Peter Schafer⁹, Zhaohui Liu⁹, Allison Gaudy⁹, Nataliya Agafonova⁹ and Nikolay Delev⁹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Military Medical Academy, Belgrade, Serbia, ⁶Instituto CER S.A., Buenos Aires, Argentina, ⁷Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ⁸Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ⁹Bristol Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
Abstract Number: 1136 • ACR Convergence 2020
Survey of Medical Cannabis Use in Lupus and Scleroderma
Wassim Karkache¹ and Catherine Ivory², ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: Despite the lack of research regarding medical cannabis, marijuana and its by-products have gained popularity over the last decades. A 2019 Statistics Canada report…
Abstract Number: 1268 • ACR Convergence 2020
Structural Validity of a Comprehensive Neuropsychological Battery for Assessment of Cognitive Impairment in Systemic Lupus Erythematosus: Exploratory Factor Analysis Confirms Six Cognitive Domains
Bahar Moghaddam¹, Robin Green², Dorcas Beaton³, Kathleen Bingham⁴, Mahta Kakvan⁵, Lesley Ruttan², Carmela Tartaglia⁶, Marvin Fritzler⁷, May Choi⁸, Jiandong Su⁵, Juan Pablo Diaz-Martinez⁵, Dennisse Bonilla⁵, Nicole Anderson⁵, Joan Wither⁵, Patricia Katz⁹ and Zahi Touma¹, ¹University of Toronto, toronto, ON, Canada, ²Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ³Institute for Work & Health, Toronto, ON, Canada, ⁴Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁹University of California, San Francisco, Novato, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to neuropsychiatric manifestations including cognitive impairment (CI). The gold standard for assessment of SLE cognitive function is the…
Abstract Number: 1284 • ACR Convergence 2020
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
Sarah Lieber¹, Patricia Katz², Joshua Baker³, Deanna Jannat-Khah⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²University of California, San Francisco, Novato, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital for Special Surgery, New York City, NY
Background/Purpose: Patients with SLE are at risk for both skeletal muscle loss and increased adiposity, which may predispose to worse health-related quality of life. Decreased…
Abstract Number: 1300 • ACR Convergence 2020
Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach
Juan Pablo Diaz-Martinez¹, Kathleen Bingham², Robin Green³, Dorcas Beaton⁴, Mahta Kakvan¹, Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su¹, Dennisse Bonilla¹, Nicole Anderson¹, Joan Wither¹, Patricia Katz⁸ and Zahi Touma⁹, ¹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University of California, San Francisco, Novato, CA, ⁹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is usually operationalized on the American College of Rheumatology Neuropsychological Battery (ACR-NB) as a z-score of ≤-1.5 on ≥2 domains or…
Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Yevgeniya Gartshteyn¹, Adam Mor², Daichi Shimbo², Leila Khalili³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵, Roberta Vezza Alexander⁶, Thierry Dervieux⁷ and Anca Askanase², ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University Medical Center, New Haven, CT, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁶Exagen Inc, Vista, CA, ⁷Prometheus Biosciences Inc, Irvine, CA
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…
Abstract Number: 1669 • ACR Convergence 2020
Genetics of Age at Diagnosis in Systemic Lupus Erythematosus
Raffaella Carlomagno¹, Fangming Liao², JingJing Cao², Dafna Gladman³, Marisa Klein-Gitelman⁴, Andrea Knight⁵, Deborah Levy¹, Karen Onel⁶, Andrew Paterson², Christine Peschken⁷, Janet Pope⁸, Zahi Touma⁹, Murray Urowitz¹⁰, Declan Webber¹, Joan Wither¹¹, Earl D. Silverman¹² and Linda Hiraki¹³, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁸Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰University Health Network, University of Toronto, Toronto, ON, Canada, ¹¹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ¹²Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ¹³Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Genome wide association studies (GWAS) have identified >90 SNPs associated with systemic lupus erythematosus (SLE) risk. However, there may be additional loci impacting the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.